Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference


SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that an abstract related to its FIERCE-22 trial of the company’s lead therapeutic, vofatamab, has been accepted for an oral and poster presentation at the upcoming 2019 American Association for Cancer Research (AACR) Bladder Cancer; Transforming the Field Special Conference, taking place May 18-21, 2019 in Denver, Colorado. “This presentation will highlight http://www.businesswire.com/news/home/20190509005350/en/Rainier-Therapeutics-Announces-Upcoming-Oral-Poster-Presentation/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==